These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29436713)

  • 21. Maternal plasma genome-wide cell-free DNA can detect fetal aneuploidy in early and recurrent pregnancy loss and can be used to direct further workup.
    Yaron Y; Pauta M; Badenas C; Soler A; Borobio V; Illanes C; Paz-Y-Miño F; Martinez-Portilla R; Borrell A
    Hum Reprod; 2020 May; 35(5):1222-1229. PubMed ID: 32386059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of non-invasive prenatal testing in pregnancies with ultrasound anomalies.
    Beulen L; Faas BHW; Feenstra I; van Vugt JMG; Bekker MN
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):721-728. PubMed ID: 27515011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide detection of additional fetal chromosomal abnormalities by cell-free DNA testing of 15,626 consecutive pregnant women.
    Yao H; Gao Y; Zhao J; Zhang R; Xu H; Hu H; Luo Y; Yuan Y; Fu M; Zhang H; Jiang H; Wang W; Yang H; Wang J; Liang Z; Chen F
    Sci China Life Sci; 2019 Feb; 62(2):215-224. PubMed ID: 30076564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Use of Ultrasound as a Potential Adjunct to Cell-Free Fetal DNA Screening for Aneuploidy at Weill Cornell Medical College, New York, USA.
    Scholl J; Chasen S
    Surg J (N Y); 2018 Jan; 4(1):e1-e6. PubMed ID: 29435489
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of first-tier cell-free DNA screening for common aneuploidies with conventional publically funded screening.
    Langlois S; Johnson J; Audibert F; Gekas J; Forest JC; Caron A; Harrington K; Pastuck M; Meddour H; Tétu A; Little J; Rousseau F
    Prenat Diagn; 2017 Dec; 37(12):1238-1244. PubMed ID: 29080223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigating Pregnancy Outcomes After Abnormal Cell-Free DNA Test Results.
    Lu J; Saller DN; Fraer LM; Chen BA
    J Genet Couns; 2018 Aug; 27(4):902-908. PubMed ID: 29368276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of the first trimester ultrasound in the era of cell free DNA screening.
    Rao RR; Valderramos SG; Silverman NS; Han CS; Platt LD
    Prenat Diagn; 2016 Dec; 36(13):1192-1198. PubMed ID: 27813114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the role of the 11- to 14-week ultrasound in women with negative cell-free DNA screening for aneuploidy?
    Reiff ES; Little SE; Dobson L; Wilkins-Haug L; Bromley B
    Prenat Diagn; 2016 Mar; 36(3):260-5. PubMed ID: 26748490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities.
    Kagan KO; Sonek J; Wagner P; Hoopmann M
    Arch Gynecol Obstet; 2017 Oct; 296(4):645-651. PubMed ID: 28702698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Where have all the trisomies gone?
    Palomaki GE; Lambert-Messerlian GM; Haddow JE
    Am J Obstet Gynecol; 2016 Nov; 215(5):583-587.e1. PubMed ID: 27793310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter clinical experience with non-invasive cell-free DNA screening for monosomy X and related X-chromosome variants.
    Bedei I; Gehrke T; Gloning KP; Meyer-Wittkopf M; Willner D; Krapp M; Scharf A; Degenhardt J; Heling KS; Kozlowski P; Trautmann K; Jahns KM; Geipel A; Baumüller JE; Wilhelm L; Gottschalk I; Schröer A; Graf A; Wolter A; Schenk J; Weber A; Van den Veyver IB; Axt-Fliedner R
    Prenat Diagn; 2023 Feb; 43(2):192-206. PubMed ID: 36726284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosomal abnormalities not currently detected by cell-free fetal DNA: a retrospective analysis at a single center.
    Shani H; Goldwaser T; Keating J; Klugman S
    Am J Obstet Gynecol; 2016 Jun; 214(6):729.e1-729.e11. PubMed ID: 26721783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-free fetal DNA analysis in maternal plasma as screening test for trisomies 21, 18 and 13 in twin pregnancy.
    Le Conte G; Letourneau A; Jani J; Kleinfinger P; Lohmann L; Costa JM; Benachi A
    Ultrasound Obstet Gynecol; 2018 Sep; 52(3):318-324. PubMed ID: 28833712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of cell-free fetal DNA on invasive prenatal diagnostic tests in a real-world public setting.
    Herraiz I; Villalba A; Ajuria E; Barasoain A; Mendoza A; Pizarro N; Escribano D; Galindo A
    J Perinat Med; 2019 Jul; 47(5):547-552. PubMed ID: 30849049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cell-free fetal DNA analysis in maternal plasma as a screening test for trisomy 21 in twin pregnancies].
    Le Conte G; Letourneau A; Jani J; Kleinfinger P; Lohmann L; Costa JM; Benachi A
    Gynecol Obstet Fertil Senol; 2018; 46(7-8):580-586. PubMed ID: 29929941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical utility of genome-wide non invasive prenatal screening.
    Fiorentino F; Bono S; Pizzuti F; Duca S; Polverari A; Faieta M; Baldi M; Diano L; Spinella F
    Prenat Diagn; 2017 Jun; 37(6):593-601. PubMed ID: 28423190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of noninvasive prenatal screening with cell-free DNA in late pregnancy with sonographic soft markers.
    Wan JH; Zhen L; Han J; Pan M; Yang X; Li DZ
    Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():431-433. PubMed ID: 32721841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ultrasound soft markers and fetal cardiac structural assessment at 11-14 weeks].
    Yang Y; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2014 Mar; 49(3):188-92. PubMed ID: 24820303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for Sex Chromosome Aneuploidy by Cell-Free DNA Testing: Patient Choice and Performance.
    Bevilacqua E; Ordóñez E; Hurtado I; Rueda L; Mazzone E; Cirigliano V; Jani JC
    Fetal Diagn Ther; 2018; 44(2):98-104. PubMed ID: 28848190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cost-effectiveness analysis comparing two different strategies in advanced maternal age: Combined first-trimester screening and maternal blood cell-free DNA testing.
    Pan M; Huang LY; Zhen L; Li DZ
    Taiwan J Obstet Gynecol; 2018 Aug; 57(4):536-540. PubMed ID: 30122574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.